Stereotactic Breast Biopsy QC

Stereotactic breast biopsy places a needle precisely at a mammographically detected target — usually microcalcifications visible on the mammogram but not on ultrasound — by using two angled x-ray projections to compute the target's depth. Because the whole value of the procedure depends on hitting a millimeter-scale target, a disciplined quality-control (QC) program built around a localization-accuracy test is essential, complemented by image-quality, dose, and mechanical checks.¹²³

A well-run QC program verifies that the biopsy device reaches the computed target within about a millimeter, that image quality is good enough to see faint calcifications, and that dose stays as low as reasonably achievable — the combination that makes the procedure accurate, safe, and defensible under ACR accreditation.¹²⁴

Introduction

When a screening or diagnostic mammogram shows suspicious microcalcifications or a small mass that ultrasound cannot see, stereotactic (or, on newer systems, tomosynthesis-guided) breast biopsy is the standard way to sample it. The patient is positioned with the breast compressed, the lesion is identified, and the system computes its three-dimensional coordinates from a stereo pair of images. A vacuum-assisted or core needle is then driven to those coordinates and tissue is sampled.³

The procedure lives or dies on geometric accuracy. A target only a few millimeters across leaves little margin: if the computed coordinates or the mechanical positioning are off by more than about a millimeter, the device can miss the calcifications entirely, producing a non-diagnostic sample, a repeat procedure, and a delayed diagnosis. That is why the localization-accuracy test is the centerpiece of stereotactic biopsy QC, and why a medical physicist's oversight matters.¹²

This guide explains how the stereo geometry computes depth, the QC tests and tolerances that keep a unit accurate, the worked math behind the depth calculation, the clinical impact of accuracy and image quality, practical optimization tips, and the regulatory framework.

Topic Explanation

How stereotactic targeting works

Stereotactic targeting recovers a target's depth from parallax. With the breast compressed against a fixed image receptor, the system acquires two exposures with the x-ray tube angled to either side of vertical — conventionally about +15° and −15°, a 30° stereo separation. A structure at the reference (receptor) plane appears in the same place in both images, but a target above that plane appears shifted horizontally between the two views. The size of that shift encodes the target's depth, which the system converts into the distance the needle must travel.³

Once the target is digitized in both stereo views, the unit computes its horizontal, vertical, and depth coordinates, and the biopsy device — mounted on a motorized stage — is driven to the pre-fire position. After firing and sampling, post-fire images confirm the needle's relationship to the target. The entire chain from image geometry through mechanical motion must be accurate to within about a millimeter.¹³

Why quality control is non-negotiable

Every link in that chain can drift. The detector can develop artifacts that obscure calcifications; the stereo geometry can be miscalibrated; the biopsy stage can lose mechanical accuracy; the compression and coordinate reference can shift. A QC program exists to catch each of these before it causes a missed target in a patient. Unlike a purely diagnostic mammography unit, a biopsy system couples imaging performance to mechanical action, so its QC must test both.¹²

Key Technical Principles

The depth-from-parallax calculation

The core physics is a parallax measurement. Consider a target at perpendicular depth $Z$ above the image receptor. When the tube is angled by $+\theta$ and then $-\theta$ from vertical, the target's projected position shifts horizontally. Under the standard small-geometry approximation, the total horizontal shift $\Delta x$ between the two stereo images is:

Solving for the depth that the system must compute:

For the conventional $\theta =15^{\circ }$ stereo pair, $2\tan 15^{\circ }=0.536$. As a worked example, if a calcification cluster shifts by $\Delta x=10.7$ mm between the +15° and −15° images:

so the target lies about 20 mm above the receptor. The sensitivity of $Z$ to the measured shift is why sub-millimeter accuracy in digitizing the target — and in the mechanical stage that acts on the result — is essential: a small error in $\Delta x$ propagates directly into the depth the needle travels.¹³

The localization-accuracy test and its tolerance

The single most important QC test is the localization (targeting) accuracy test, performed with a phantom containing a known target. The operator localizes the target using the normal clinical stereo workflow, drives the biopsy device to it, and measures how far the device actually lands from the true target position. Vendor daily accuracy tests and accreditation programs require this error to be small: in a published Medical Physics evaluation of stereotactic and tomosynthesis-guided biopsy units, both systems passed the vendor-provided daily localization-accuracy test with a nominal error under 1 mm in each dimension.¹

That roughly 1 mm criterion — verified before first clinical use, after service, and on a routine schedule — is the acceptance threshold that keeps the procedure trustworthy. An early phantom method described visual detection of localization faults specifically in the z-axis (the biopsy depth direction), reflecting how central depth accuracy is to the test.²

Sources of targeting error

Because the depth calculation is so sensitive to the measured parallax, it helps to know where error creeps in. Several independent contributions can degrade targeting accuracy, and a good QC program is designed to catch each:

• Digitization error — imprecise marking of the target center in the two stereo views feeds directly into $\Delta x$ and therefore into the computed depth.
• Geometric miscalibration — if the actual tube angulation differs from the nominal ±15°, or the stereo geometry is mis-set, the depth conversion is biased.
• Mechanical stage inaccuracy — even a perfectly computed coordinate is only useful if the motorized biopsy stage physically reaches it; backlash or drift in the stage introduces its own error.
• Patient motion and compression slippage — if the breast shifts between the stereo pair and the fire, the target moves relative to the computed coordinates.
• Detector artifacts — a bad pixel line or ghost can shift the apparent target position or hide it entirely.

The published localization-accuracy framework separates these by measuring stroke-length error, the Euclidean distance between the target and the needle trough, and the longitudinal and lateral offsets — each of which points at a different failure mode. That is why the accuracy test is quantitative and multi-dimensional rather than a single pass/fail glance.¹

The QC test set

A stereotactic biopsy QC program combines mechanical/accuracy tests with mammographic image-quality and dose tests. The table lists representative components; the exact frequencies and pass/fail criteria are defined by the unit's manufacturer and the ACR Stereotactic Breast Biopsy Accreditation Program, which a qualified medical physicist and the technologists implement together.³⁴⁵

At least one localization-accuracy test and a phantom image-quality check anchor the routine program, while the medical physicist's annual survey ties accuracy, image quality, and dose together into the documentation required for accreditation, consistent with the ACR–AAPM technical standard for mammography physics performance monitoring.⁴⁵⁸

Clinical Impact

Targeting accuracy and image quality translate directly into diagnostic yield. When a unit is accurate to within a millimeter and its imaging clearly shows the calcifications, the biopsy retrieves representative tissue on the first attempt, the pathology is reliable, and the patient avoids a repeat procedure. When accuracy drifts or image quality degrades, the device can miss the target or sample adjacent tissue, producing a false-negative or non-diagnostic result.¹³

The clinical stakes are well studied. In a randomized controlled trial comparing 11-gauge vacuum-assisted biopsy with 14-gauge core needle biopsy for mammographic microcalcification, both approaches achieved high diagnostic accuracy — but that performance presupposes an accurately targeted, well-imaged procedure.⁶ QC is what makes the assumed accuracy real. A unit that quietly falls out of tolerance can undermine an otherwise excellent clinical technique.

Dose matters too. Stereotactic biopsy involves scout, stereo-pair, pre-fire, and post-fire images, so the cumulative breast dose depends on technique and workflow. Keeping mean glandular dose as low as reasonably achievable — while preserving the image quality needed to see calcifications — is a balance the physicist evaluates during the annual survey, using the same dose principles that govern screening mammography. For the underlying dose metric, see our guide to mean glandular dose in mammography.

Practical Optimization Tips

Make the accuracy test a daily habit

Run the localization-accuracy phantom test on the schedule the manufacturer and accreditation program require, and always after any service that could affect geometry or the biopsy stage. Treat an out-of-tolerance result as a hard stop: do not biopsy patients until accuracy is restored and re-verified.¹⁴

Protect image quality for faint calcifications

Because the targets are often subtle specks, keep the detector, technique factors, and image processing tuned so microcalcifications are clearly visible. Include artifact evaluation in routine QC — a single bad detector line or ghost can hide or mimic a target. Coordinate this with the facility's broader mammography QC under the ACR Digital Mammography QC Manual.

Verify with pre- and post-fire imaging

Use the pre-fire and post-fire images as an in-procedure QC check on every case: they confirm the needle's actual relationship to the target and catch a mis-target before the sample is taken. Document these as part of the procedure record.

Confirm retrieval with specimen radiography

When the target is microcalcifications, specimen radiography — imaging the excised cores to confirm the calcifications were actually captured — is the immediate feedback that the targeting worked on this patient. Keep the specimen imaging device (a dedicated cabinet or the biopsy unit itself) within its own QC program so that a faint calcification is not missed on the specimen image and mistaken for a failed retrieval. Correlating specimen radiography with the pathology report closes the loop between accurate targeting and a reliable diagnosis.

Keep dose and image quality in balance

During the annual survey, evaluate mean glandular dose against the technique needed to visualize the target, and optimize rather than simply minimize — too little dose can lose the calcifications, too much adds unnecessary exposure. Tie the dose assessment to the facility's accreditation dossier.

Document for accreditation

Maintain organized QC logs — accuracy tests, phantom scores, artifact checks, dose, and the physicist's annual report — so the ACR accreditation submission is a matter of assembling existing records rather than a scramble. For the accreditation framework, see our overview of ACR accreditation physics requirements.

Extend the same discipline to tomosynthesis-guided biopsy

Newer units localize targets from a tomosynthesis sweep rather than a classic stereo pair, but the QC philosophy is identical: verify localization accuracy with a phantom, confirm image quality, and survey the system annually. Published frameworks now quantify localization error for tomosynthesis-guided units as well, so the accuracy discipline carries directly over.¹

Regulatory Considerations

Stereotactic breast biopsy is governed primarily by accreditation and practice standards rather than a single federal quality mandate. The relevant frameworks are:

• FDA MQSA / 21 CFR Part 900 — the Mammography Quality Standards Act regulates mammography for screening and diagnosis. Image-guided breast biopsy is a guidance procedure, so the biopsy function itself generally falls outside MQSA certification, though the diagnostic mammography performed at the facility remains MQSA-regulated.⁷
• ACR Practice Parameter for the Performance of Stereotactic/Tomosynthesis-Guided Breast Interventional Procedures — the professional standard describing personnel qualifications, procedure performance, and quality assurance expectations.³
• ACR Stereotactic Breast Biopsy Accreditation Program — the external QC framework, specifying phantom testing, routine QC, and the qualified medical physicist's annual survey; its QC and phantom-testing requirements are periodically revised, so facilities should work from the current program materials.⁴
• ACR Digital Mammography QC Manual — the mammographic image-quality and dose QC backbone that applies to the imaging chain of biopsy units.⁵

Radiation-producing equipment is also regulated by state radiation-control programs. In Florida, x-ray machines — including stereotactic biopsy units — are registered and inspected by the Florida Department of Health, Bureau of Radiation Control, under Chapter 64E-5, Florida Administrative Code (Part V governs x-ray machines).⁹ DRPS also serves Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware, where parallel state radiation-control requirements apply. Always confirm requirements with the authority having jurisdiction.

Frequently Asked Questions (FAQs)

What is stereotactic breast biopsy?

It is a minimally invasive procedure that uses mammographic imaging to guide a needle to a suspicious finding — most often microcalcifications — that is visible on the mammogram but not on ultrasound. Two angled projections are acquired so the system can compute the three-dimensional location of the target and drive a vacuum-assisted or core needle to it.

How accurate does a stereotactic biopsy unit have to be?

The system must reach the computed target with high precision. Vendor and accreditation localization-accuracy tests typically require the biopsy device to reach the target with an error under about 1 millimeter in each dimension, verified with a phantom before clinical use and on a routine schedule.

How does the stereo pair compute depth?

Two exposures are taken with the x-ray tube angled to each side of vertical, conventionally about plus and minus 15 degrees. A target below the reference plane shifts horizontally between the two images, and that parallax shift is converted into depth by the system geometry, so the needle can be advanced to the correct distance.

Who performs the quality control?

Technologists perform daily and other routine QC such as phantom image quality and the localization-accuracy check, while a qualified medical physicist performs the annual survey — evaluating accuracy, image quality, dose, and system performance — and provides the documentation required for ACR accreditation.

Is stereotactic breast biopsy covered by MQSA?

The federal Mammography Quality Standards Act regulates mammography for screening and diagnosis. Image-guided breast biopsy is a guidance procedure rather than mammography, so the biopsy function itself generally falls outside MQSA certification; in practice, ACR accreditation and its quality-control program provide the external quality framework for stereotactic biopsy units.

What image quality is required for a biopsy unit?

Because the target is often faint microcalcifications, image quality must be sufficient to see and localize them reliably. Phantom scoring, signal-to-noise and contrast checks, artifact evaluation, and detector performance are all part of routine and annual QC, with the goal that biopsy imaging meets the standard needed to confidently identify the target.

Key Takeaways

• Stereotactic breast biopsy computes a target's depth from the parallax between two angled projections, conventionally at ±15°.
• The localization-accuracy test is the centerpiece of QC: the device should reach a phantom target within about 1 mm in each dimension.
• Because a small parallax error propagates into depth, sub-millimeter accuracy in both targeting and the mechanical stage is essential.
• QC couples image quality (visualizing faint calcifications) with mechanical accuracy — biopsy units must test both.
• Dose is optimized, not just minimized: enough to see the calcifications, no more, evaluated at the physicist's annual survey.
• ACR accreditation and its QC program provide the external quality framework, since the biopsy function falls outside MQSA certification.

Conclusion

Stereotactic breast biopsy is a triumph of applied geometry: a millimeter-scale calcification cluster, invisible to ultrasound, is reached with a needle by turning parallax into depth. That precision is only as good as the quality-control program behind it. A facility that runs the localization-accuracy test faithfully, protects the image quality needed to see the target, keeps dose optimized, and documents a physicist's annual survey will deliver accurate, low-dose, accreditation-ready biopsies — and the reliable diagnoses that depend on them.

How DRPS Can Help

Diagnostic Radiation Physics Services supports breast imaging facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with mammography physics and MQSA services, stereotactic and tomosynthesis-guided biopsy surveys, localization-accuracy and image-quality testing, dose optimization, and accreditation support — delivered by board-certified medical physicists.

A strong biopsy QC program is not just about passing accreditation. It is about making sure that when a needle is driven to a millimeter-scale target in a patient, it gets there.

Related Resources

• Mammography quality control and MQSA
• Digital breast tomosynthesis QC
• Mean glandular dose in mammography
• Contrast-enhanced mammography QC
• ACR accreditation physics requirements
• Mammography physics & MQSA
• Accreditation support

References

1. Nosrati R, Zhang D, MacDougall RD, Phillips J, Palmer MR. Development of a novel framework to evaluate the localization accuracy of tomosynthesis-guided breast biopsy units. Med Phys. 2021;48(3):1299-1306. doi:10.1002/mp.14724. doi.org
2. Krämer S, Schulz-Wendtland R, Lang N. Quality assurance in stereotactic punch biopsy using a phantom. Aktuelle Radiol. 1996;6(3):153-155. PubMed
3. American College of Radiology. ACR Practice Parameter for the Performance of Stereotactic/Tomosynthesis-Guided Breast Interventional Procedures. Reston, VA: ACR. acr.org
4. American College of Radiology. Stereotactic Breast Biopsy Accreditation Program: Quality Control and Phantom Testing Requirements. Reston, VA: ACR. acr.org
5. American College of Radiology. ACR Digital Mammography Quality Control Manual. Reston, VA: ACR. acr.org
6. Bundred SM, Maxwell AJ, Morris J, et al. Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification. Br J Radiol. 2015;89(1058):20150504. doi:10.1259/bjr.20150504. doi.org
7. U.S. Food and Drug Administration. Mammography Quality Standards Act (MQSA) and 21 CFR Part 900. fda.gov
8. American College of Radiology. ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Mammography Equipment. Reston, VA: ACR. acr.org
9. Florida Department of Health, Bureau of Radiation Control. Florida Administrative Code Chapter 64E-5: Control of Ionizing Radiation Hazards. flrules.org